GSK Plc halted development of an experimental drug for chronic cough, saying it was “unlikely to transform patient care.” ...
GSK on Friday said it had decided not to develop its experimental drug to treat refractory chronic cough further after it did not meet one of its main goals in a late-stage trial.
GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 catalyst for the ...
A 12-week prospective cohort enrolled 73 patients with guideline-based asthma or COPD and no speech-affecting comorbidities, ...
Here's why pneumonia is such a serious problem for seniors — and what signs and symptoms you should look out for.
Pneumonia can affect people of all ages, but older adults are at a much higher risk of developing severe illness and ...
Toronto has some of the world's worst air quality this week. (Photo via THE CANADIAN PRESS/Laura Proctor) But how do you know ...
The FDA has accepted Apnimed’s NDA for AD109 (aroxybutynin/atomoxetine), a potential first-in-class oral therapy for adults with obstructive sleep apnea.
In one phase 3 trial, former smokers with COPD receiving itepekimab had a significantly lower annualized moderate/severe ...
WE’VE all been enjoying the hot weather this summer. But it is important to remember that the Met Office issues serious heat ...
Introduction Patients with chronic bronchitis suffer high morbidity and rapid functional decline; thus, novel treatments are ...
As wildfire smoke becomes an increasingly common consequence of climate change, clinicians are facing new challenges in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results